Julius Clinical

FierceBiotech | February 03, 2020

Gilead has made progress in its effort to reposition failed Ebola drug remdesivir as a treatment for the coronavirus sweeping across China. In quick succession, it emerged that the nucleotide analogue prodrug appeared to help the first U.S. case of the virus and is set to undergo clinical testing in China, sending Gilead’s stock up by as much as 13% in premarket trading. Remdesivir was one of a clutch of drugs tested against Ebola, but it failed to match the efficacy of its rivals, leading...

Business Insights

Orsini Specialty Pharmacy | September 28, 2021

Orsini Specialty Pharmacy, the leading independent specialty pharmacy focused on rare diseases and gene therapies, announced that Sanofi has selected it as a limited distribution partner for Nexviazyme® (avalglucosidase alfa-ngpt). Nexviazyme, an enzyme replacement therapy (ERT), is used for treating patients one year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency). This progressive and debilitating muscle disorder impairs a person's abi...

Business Insights

Vetsource | February 28, 2022

Vetsource®, a pet health company that provides innovative pharmacy, technology and business services designed to help customers provide products and services to those who care for pets, has added data and insights, and client engagement offerings to its portfolio of customer solutions. Previously focused primarily on the home delivery of prescription and nonprescription items on behalf of veterinary practices, Vetsource has expanded its services in order to build a world-class...

Business Insights

Aqemia | February 15, 2022

Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum-inspired physics announces it has entered into a pilot study agreement with Janssen. Through the agreement Aqemia’s unique technology to predict the potency of small molecules for a given target based on physics-based calculations will be applied to selected Janssen datasets. The agreement aims at building a common understanding of the performance of Aqemia’s technolog...